Lipocine Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. Lipocine is a clinical-stage biopharmaceutical company developing oral therapies; it has not generated product sales. Financial statements are unaudited.
Financial performance and position
| Metric | Q1 2021 | Q1 2020 / prior date |
|---|---|---|
| Revenue | No revenue shown in the statements of operations | No revenue shown |
| Research and development expense | $1.58 million | $2.51 million |
| General and administrative expense | $1.53 million | $2.09 million |
| Operating loss | $3.11 million | $4.60 million |
| Net loss | $3.37 million | $5.77 million |
| Basic and diluted loss per share | $0.04 | $0.14 |
| Cash used in operating activities | $4.06 million | $3.38 million |
| Unrestricted cash, cash equivalents and marketable securities | $50.0 million | $19.7 million at December 31, 2020 |
| Debt carrying value | $4.78 million | $5.59 million at December 31, 2020 |
Operating margins are not meaningful given the absence of reported revenue. Total assets were $50.58 million and stockholders’ equity was $42.39 million at March 31, 2021. Cash and cash equivalents were $15.60 million; marketable securities were $34.36 million. Cash used in investing activities was $33.99 million, primarily reflecting purchases of marketable securities, while financing activities provided $29.44 million.
Changes versus the prior comparable period
- Net loss narrowed by about 42%; operating expenses declined about 32%. R&D expense fell primarily because of lower LPCN 1144 trial and consulting costs, while G&A expense fell mainly due to lower legal costs.
- Operating cash use increased from $3.38 million to $4.06 million despite the lower net loss.
- Interest and investment income decreased to $10,649 from $59,938. The noncash warrant-liability loss was $195,065, down from $1.10 million.
- Weighted-average shares increased to 81.9 million from 41.3 million; Q1 2021 equity issuance included a public offering and ATM sales.
- The company released $5.0 million of restricted cash after a February 2021 amendment removed the SVB cash-collateral requirement.
Outlook, business developments and risks
- Management said existing resources were expected to fund projected operations through at least March 31, 2022, based on assumptions that may change. The company expects to need additional capital at some point; inability to raise funds could threaten continued operations.
- TLANDO received FDA tentative approval in December 2020, but cannot receive final approval for U.S. marketing before March 27, 2022, when Clarus’s JATENZO exclusivity expires. Required post-marketing studies and pediatric requirements remain relevant if TLANDO receives full approval. Commercialization could require substantial additional spending.
- LPCN 1144’s 12-week Phase 2 results showed liver-fat and liver-marker improvements, with no observed tolerability issues reported; 36-week biopsy data were expected in August 2021. These are company-reported clinical results, not proof of approval or commercial success.
- The company expected LPCN 1148’s first subject to be dosed in the second half of 2021. TLANDO XR development includes further protocol and food-effect work. LPCN 1107’s pivotal study was not expected to start in 2021 before completion and FDA review of a food-effect study.
- SVB debt matures June 1, 2022, bears interest at prime plus 1% (4.25% at quarter-end), and includes a $650,000 final payment charge. Debt is secured by substantially all assets other than intellectual property and specified exclusions.
- Material legal matters include patent-infringement litigation against Clarus, a related patent interference proceeding, and a securities class action. The class-action outcome was described as not probable or estimable; insurance has a $1.25 million retention.
- Other risks include continued operating losses, dependence on future financing, clinical and regulatory uncertainty, competition, potential dilution, and volatility in the stock and warrant-liability valuation. Management reported disclosure controls were effective at March 31, 2021.
Important facts for investors to verify
- Progress and timing of TLANDO final FDA approval, launch readiness, and the required post-marketing studies.
- Whether LPCN 1144’s expected 36-week results support further development and what additional trial costs may follow.
- Cash burn, the March 2022 stated runway assumptions, and the timing and terms of any additional financing.
- SVB debt repayment and final payment obligations, plus the status and potential cost of the Clarus and shareholder litigation.
- Share-count changes and remaining authorized shares: 88.29 million common shares were outstanding at quarter-end, against 100 million authorized.